KRYS logo

KRYS
Krystal Biotech Inc

1,821
Mkt Cap
$9.03B
Volume
316,531.00
52W High
$319.48
52W Low
$122.80
PE Ratio
40.94
KRYS Fundamentals
Price
$306.29
Prev Close
$316.30
Open
$312.29
50D MA
$268.74
Beta
0.98
Avg. Volume
242,837.73
EPS (Annual)
$6.84
P/B
7.06
Rev/Employee
$1.32M
$6,565.67
Loading...
Loading...
News
all
press releases
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
KRYS shares jump after a Q1 beat as Vyjuvek fuels 32% revenue growth, strong uptake and global expansion, with pipeline catalysts lined up through 2026.
Zacks·12d ago
News Placeholder
More News
News Placeholder
Krystal Biotech (NASDAQ:KRYS) Sets New 52-Week High After Better-Than-Expected Earnings
Krystal Biotech (NASDAQ:KRYS) Reaches New 12-Month High After Better-Than-Expected Earnings...
MarketBeat·12d ago
News Placeholder
HC Wainwright Reiterates "Buy" Rating for Krystal Biotech (NASDAQ:KRYS)
HC Wainwright reissued a "buy" rating and issued a $310.00 price target on shares of Krystal Biotech in a research note on Monday...
MarketBeat·13d ago
News Placeholder
Krystal Biotech Q1 Earnings Call Highlights
Krystal Biotech (NASDAQ:KRYS) reported first-quarter 2026 net revenue of $116.4 million from global sales of VYJUVEK, supported by continued demand in the U.S. and early traction in Europe and Japan. Management highlighted positive operating leverage, a 95% gross margin, and an expanding clinical pi...
MarketBeat·13d ago
News Placeholder
Krystal Biotech Q1 2026 Earnings Call Transcript
read more...
Benzinga·13d ago
News Placeholder
Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +26.21% and +3.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·13d ago
News Placeholder
Vanguard Group Inc. Trims Stock Position in Krystal Biotech, Inc. $KRYS
Vanguard Group Inc. reduced its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 0.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,778,845 shares of the company's stock after se...
MarketBeat·14d ago
News Placeholder
Krystal Biotech (NASDAQ:KRYS) Releases Quarterly Earnings Results, Beats Expectations By $0.38 EPS
Krystal Biotech (NASDAQ:KRYS - Get Free Report) announced its earnings results on Monday. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. The firm had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million...
MarketBeat·14d ago
News Placeholder
Krystal Biotech, Inc. Bottom Line Climbs In Q1
(RTTNews) - Krystal Biotech, Inc. (KRYS) reported a profit for its first quarter that Increased, from the same period last year...
Nasdaq News: Markets·14d ago
News Placeholder
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of +20.40% and +211.90%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·17d ago
<
1
2
...
>

Latest KRYS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.